Literature DB >> 21067751

Leptin receptor-induced STAT3-independent signaling pathways are protective against atherosclerosis in a murine model of obesity and hyperlipidemia.

Wei Luo1, Peter F Bodary, Yuechun Shen, Kevin J Wickenheiser, Miina K Ohman, Chiao Guo, Kristina L Bahrou, Martin G Myers, Daniel T Eitzman.   

Abstract

AIMS: Leptin is an adipocyte-derived hormone that has been shown to exert both beneficial metabolic effects and potentially adverse vascular effects in preclinical studies. The primary aim of this study was to determine the effects of leptin receptor signaling pathways on atherosclerosis in the setting of obesity and hyperlipidemia. METHODS AND
RESULTS: Mice were generated with deficiency of apolipoprotein E (ApoE(-/-)) and either wild-type leptin receptor expression (Lepr(+/+), ApoE(-/-)), mutant leptin receptor expression defective in all leptin receptor signaling pathways (Lepr(db/db), ApoE(-/-)), or mutant leptin receptor expression with selective deficiency of leptin receptor-STAT3 signaling (Lepr(s/s), ApoE(-/-)). At 27 weeks of age (including 7 weeks on a Western diet), Lepr(db/db), ApoE(-/-) developed severe obesity, hypercholesterolemia, and increased atherosclerosis compared to Lepr(+/+), ApoE(-/-) mice. Despite similar obesity and hyperlipidemia to Lepr(db/db), ApoE(-/-) mice, Lepr(s/s), ApoE(-/-) developed less atherosclerosis than Lepr(db/db), ApoE(-/-) mice. Adipose tissue macrophage content, monocyte chemoattractant protein-1 and fatty-acid-binding protein 4 levels were also reduced in Lepr(s/s), ApoE(-/-) mice compared to Lepr(db/db), ApoE(-/-) mice.
CONCLUSIONS: In a mouse model of obesity and hyperlipidemia, leptin receptor-mediated STAT3-independent signaling pathways confer protection against atherosclerosis. These differences occur independently of leptin effects on energy balance. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21067751      PMCID: PMC3018566          DOI: 10.1016/j.atherosclerosis.2010.10.009

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  28 in total

1.  Monocyte chemoattractant protein-1 deficiency protects against visceral fat-induced atherosclerosis.

Authors:  Miina K Ohman; Andrew P Wright; Kevin J Wickenheiser; Wei Luo; Hana M Russo; Daniel T Eitzman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-03-18       Impact factor: 8.311

2.  Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity.

Authors:  S Konstantinides; K Schäfer; S Koschnick; D J Loskutoff
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

3.  Effect of leptin on arterial thrombosis following vascular injury in mice.

Authors:  Peter F Bodary; Randal J Westrick; Kevin J Wickenheiser; Yuechen Shen; Daniel T Eitzman
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

4.  Leptin-replacement therapy for lipodystrophy.

Authors:  Elif Arioglu Oral; Vinaya Simha; Elaine Ruiz; Alexa Andewelt; Ahalya Premkumar; Peter Snell; Anthony J Wagner; Alex M DePaoli; Marc L Reitman; Simeon I Taylor; Phillip Gorden; Abhimanyu Garg
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

5.  Leptin-induced endothelial dysfunction in obesity.

Authors:  Mykhaylo Korda; Ruslan Kubant; Stephen Patton; Tadeusz Malinski
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-08       Impact factor: 4.733

6.  Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Miina K Ohman; Yuechun Shen; Chinyere I Obimba; Andrew P Wright; Mark Warnock; Daniel A Lawrence; Daniel T Eitzman
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

7.  Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2.

Authors:  Masato Furuhashi; Gürol Tuncman; Cem Z Görgün; Liza Makowski; Genichi Atsumi; Eric Vaillancourt; Keita Kono; Vladimir R Babaev; Sergio Fazio; MacRae F Linton; Richard Sulsky; Jeffrey A Robl; Rex A Parker; Gökhan S Hotamisligil
Journal:  Nature       Date:  2007-06-06       Impact factor: 49.962

8.  Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis.

Authors:  Soraya Taleb; Olivier Herbin; Hafid Ait-Oufella; Wim Verreth; Pierre Gourdy; Véronique Barateau; Régine Merval; Bruno Esposito; Karine Clément; Paul Holvoet; Alain Tedgui; Ziad Mallat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-08-09       Impact factor: 8.311

9.  Effect of leptin in platelet and endothelial cells. Obesity and arterial thrombosis.

Authors:  I Maruyama; M Nakata; K Yamaji
Journal:  Ann N Y Acad Sci       Date:  2000-05       Impact factor: 5.691

10.  Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity.

Authors:  Hiromasa Funato; Allen L Tsai; Jon T Willie; Yasushi Kisanuki; S Clay Williams; Takeshi Sakurai; Masashi Yanagisawa
Journal:  Cell Metab       Date:  2009-01-07       Impact factor: 27.287

View more
  4 in total

1.  Leptin upregulates smooth muscle cell expression of MMP-9 to promote plaque destabilization by activating AP-1 via the leptin receptor/MAPK/ERK signaling pathways.

Authors:  Ruijie Liu; Benfa Chen; Jiemin Chen; Jun Lan
Journal:  Exp Ther Med       Date:  2018-10-12       Impact factor: 2.447

Review 2.  Adipokines, adiposity, and atherosclerosis.

Authors:  Longhua Liu; Zunhan Shi; Xiaohui Ji; Wenqian Zhang; Jinwen Luan; Tarik Zahr; Li Qiang
Journal:  Cell Mol Life Sci       Date:  2022-05-03       Impact factor: 9.261

3.  Toll-like receptor 3 (TLR3) protects retinal pigmented epithelium (RPE) cells from oxidative stress through a STAT3-dependent mechanism.

Authors:  Amit K Patel; Abigail S Hackam
Journal:  Mol Immunol       Date:  2012-12-23       Impact factor: 4.407

4.  The mouse age phenome knowledgebase and disease-specific inter-species age mapping.

Authors:  Nophar Geifman; Eitan Rubin
Journal:  PLoS One       Date:  2013-12-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.